Post-earnings recap
Reported
Mon, Aug 3, 2026
EPS actual
$-0.94
EPS est.
$-1.10
EPS surprise
+14.62%
1-day move
+3.29%
CRISPR Therapeutics reported a narrower-than-expected loss per share, which likely contributed to the positive stock reaction of 3.29%. However, the company did not provide revenue figures or guidance, leaving some uncertainty about future performance. Investors may view the EPS beat as a sign of improved operational efficiency, but the lack of revenue data raises questions about overall growth.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.94 | $-1.06 | +14.62% |
| Revenue | — | $16M | — |
No transcript is on record, and the analysis is based on numerical results only.
CRISPR Therapeutics AG is a biotechnology company focused on developing transformative gene-based medicines using CRISPR technology. With a market cap of $5 billion, the company is at the forefront of innovative healthcare solutions, particularly in genetic therapies that could address serious diseases.
Last quarter
In Q1 2026, CRISPR reported an EPS of $-1.28, missing estimates by 12.38%. The stock reacted positively, gaining 3.78% the following day.
Management promises and guidance
EPS beat streak
1Q
EPS beat rate
50%
Avg EPS surprise
-1.76%
Avg 1-day reaction
+0.23%
Analysts are expecting a challenging quarter with a consensus EPS of $-1.06 and revenue of $16 million. There is uncertainty regarding the company's ability to meet these expectations.
Bull case
If CRISPR can demonstrate progress in its clinical trials and exceed revenue expectations, it could signal strong market demand for its therapies, leading to a positive stock reaction.
Bear case
Conversely, if the company fails to meet its EPS and revenue targets, it may raise concerns about its financial health and future growth prospects, potentially leading to a stock decline.
Key metrics to watch
EPS
$-1.06Earnings per share is a key indicator of profitability and will show how well the company is managing its costs.
Revenue
$16MRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will CRISPR's revenue exceed the $16 million consensus estimate?
A revenue beat would indicate strong demand for its therapies and could boost investor confidence.
Q2
How will the company address its ongoing losses reflected in the EPS forecast?
Investors will be keen to hear about strategies for improving profitability and managing costs.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating the potential for CRISPR's therapies to gain traction in the market, driven by recent advancements in gene editing.
Supporting evidence
The stock has historically reacted positively even after misses, indicating resilience.
Recent clinical trial updates suggest progress that may not be fully reflected in current estimates.
Key risk
If revenue comes in significantly above $16 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is weighing CRISPR's ability to manage costs and generate revenue against its history of losses.
Bull confirmed if
Achieving revenue above $16 million and an EPS closer to the consensus would confirm a bullish outlook.
Bear confirmed if
An EPS significantly worse than $-1.06 and revenue below expectations would confirm a bearish outlook.
What the market is pricing for the move.
Implied Move
±26.4%
Historical Avg
±3.5%
The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation surrounding the earnings report.
Options are pricing ±26.4% while CRSP has averaged ±3.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
61.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CRISPR beats expectations, history suggests the stock could see a modest increase, confirming a positive growth outlook.
In line / cautious
If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to volatility.
Miss
Should the company miss estimates, history suggests a potential decline in stock price, reflecting investor disappointment.
The lines on the call that would change the story.